Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Ryan

Endocrinology, Diabetes & Metabolism Martinsburg, WV Medical Doctor

NPI 1043396229 CMS profile 184052

176 Health Care Ln, Suite B, Martinsburg, WV 25401

Open in the dashboard

General payments

$35,390

741 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Ryan of Martinsburg, WV is reported in the CMS Open Payments database as having received $35,390 across 741 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,958 96
2024 General $1,954 113
2023 General $1,618 81
2022 General $1,728 95
2021 General $3,581 111
2020 General $7,675 98
2019 General $16,877 147

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Ryan
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Philip Ryan were reported at $1,958. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Philip Ryan Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $16,877 $494 $123–$2,253 $163
2020 $7,675 $335 $85–$1,841 $114
2021 $3,581 $398 $88–$1,981 $132
2022 $1,728 $364 $88–$1,568 $149
2023 $1,618 $420 $113–$1,614 $160
2024 $1,954 $440 $121–$1,646 $164
2025 $1,958 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amarin Pharma Inc. $11,399 33 payments
  2. AbbVie, Inc. $9,439 118 payments
  3. Esperion Therapeutics, Inc. $4,318 38 payments
  4. Lilly USA, LLC $2,658 134 payments
  5. Novo Nordisk Inc $1,248 75 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $827 48 payments
  7. Abbott Laboratories $647 46 payments
  8. Amgen Inc. $642 27 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $636 34 payments
  10. Sanofi-Aventis U.S. LLC $526 32 payments
  11. Other $3,050 156 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,500 14 payments
  2. Food and Beverage $13,000 710 payments
  3. Travel and Lodging $1,865 14 payments
  4. Education $25 3 payments
Products named General payments · program years 2019–2025
  1. Vascepa $11,291 26 payments
  2. NEXLETOL $4,318 38 payments
  3. Synthroid Endocrinology $4,041 22 payments
  4. NEXLIZET $3,795 6 payments
  5. SYNTHROID Immunology $3,400 78 payments
  6. Ozempic $1,178 71 payments
  7. JARDIANCE Diabetes $1,049 50 payments
  8. RYBELSUS $938 54 payments
  9. MOUNJARO $898 45 payments
  10. JARDIANCE Diabetes $763 45 payments
  11. Other $8,383 456 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

4,275

Median for Endocrinology: 1,959

Drug cost

$1,500,811

Median for Endocrinology: $890,201

Branded share of claims

35%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 224 $442,472
Trulicity Dulaglutide Brand 125 $177,458
Glyxambi Empagliflozin/Linagliptin Brand 101 $157,661
Ozempic Semaglutide Brand 86 $138,662
Jardiance Empagliflozin Brand 75 $98,799
Premarin Estrogens, Conjugated Brand 132 $60,679
Januvia Sitagliptin Phosphate Brand 63 $49,567
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 36 $45,723
Tresiba Flextouch U-200 Insulin Degludec Brand 20 $41,734
Tradjenta Linagliptin Brand 19 $24,941

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$47,075

Of which drugs: $394

Medicare patients

184

Average age 71

Services billed

1,261

93 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Diabetes 72%
Arthritis 48%
Chronic kidney disease 29%
Depression 22%
Osteoporosis 22%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 18 18 $394

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $342
$342 224 —
SYNTHROID
  • AbbVie, Inc. $211
$211 135 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $186
$186 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $139
$139 — —
JARDIANCE
  • Lilly USA, LLC $129
$129 75 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

741 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record